From Wikipedia, the free encyclopedia
Neprilysin, also known as membrane
metallo-endopeptidase, neutral
endopeptidase (NEP), CD10, and
common acute lymphoblastic
leukemia antigen (CALLA), is a zinc-dependent metalloprotease enzyme that degrades a number of small secreted
peptides, most notably the amyloid beta peptide
whose abnormal misfolding and aggregation in neural tissue has been implicated as a
cause of Alzheimer's disease. Synthesized as
a membrane-bound protein, the neprilysin
ectodomain is released into the extracellular domain after it has
been transported from the Golgi apparatus to the cell surface. In
neurons, neprilysin is
regulated by the protein nicastrin, a component of the gamma secretase
complex that performs a necessary step in processing amyloid precursor protein to
amyloid beta.[1]
Amyloid
beta regulation
Mutations in the neprilysin gene have been associated with
familial forms of Alzheimer's disease,[2]
and neprilysin-deficient knockout mice show both Alzheimer's-like
behavioral impairment and amyloid-beta deposition in the brain,[3]
providing strong evidence for the protein's association with the
Alzheimer's disease process. Because neprilysin is thought to be
the rate-limiting step in amyloid beta
degradation,[4]
it has been considered a potential therapeutic target; compounds
such as the peptide hormone somatostatin have been identified that
increase the enzyme's activity level.[5]
One hypothesis for the strong dependence of Alzheimer's incidence
on age focuses on the declining production of somatostatin the
brains of elderly people, which thus depresses the activity of
neprilysin and promotes aggregation of unprocessed amyloid
beta.[6]
Declining neprilysin activity with increasing age may also be
explained by oxidative damage, known to be a causative
factor in Alzheimer's disease; higher levels of inappropriately
oxidized neprilysin have been found in Alzheimer's patients
compared to cognitively normal elderly people.[7]
Signaling
peptides
Neprilysin immunohistochemical staining of normal
kidney.
Neprilysin is also associated with other biochemical processes,
and is particularly highly expressed in kidney and lung
tissues. Inhibitors have been designed with the aim of developing
analgesic and antihypertensive agents that act by
preventing neprilysin's activity against signaling peptides such as
enkephalins, substance P, endothelin, and atrial natriuretic factor.[8][9]
Associations have been observed between neprilysin expression
and various types of cancer;
however, the relationship between neprilysin expression and
carcinogenesis remains obscure. In cancer biomarker studies, the neprilysin gene is
often referred to as CD10 or CALLA. In some types of cancer, such
as metastatic carcinoma and some advanced melanomas, neprilysin is
overexpressed;[10]
in other types, most notably lung cancers, neprilysin is downregulated,
and thus unable to modulate the pro-growth autocrine signaling of
cancer cells via secreted peptides such as mammalian homologs
related to bombesin.[11]
Inhibitors
References
- ^ Pardossi-Piquard, R.; Dunys J., Yu G., St
George-Hyslop P., Alves da Costa C. and Checler F. (May 2006).
"Neprilysin activity and expression are controlled by nicastrin".
Journal of Neurochemistry 97 (4): 1052–6.
doi:10.1111/j.1471-4159.2006.03822.x. PMID 16606360.
- ^ Helisalmi, S coauthors= M. Hiltunen, S.
Vepsäläinen, S. Iivonen, A. Mannermaa, M. Lehtovirta, A. M.
Koivisto, I. Alafuzoff and H. Soininen (2004). "Polymorphisms in neprilysin
gene affect the risk of Alzheimer's disease in Finnish
patients". Journal of Neurology Neurosurgery and
Psychiatry 75 (12): 1746–8. doi:10.1136/jnnp.2004.036574. PMID 15548496. http://jnnp.bmj.com/cgi/content/full/75/12/1746. Retrieved
2007-03-11.
- ^ Madan, Rime; Raphael Poirier, David P.
Wolfer, Hans Welzl, Peter Groscurth, Hans-Peter Lipp, Bao Lu,
Mohammed El Mouedden, Marc Mercken, Roger M. Nitsch and M. Hasan
Mohajeri (December 2006). "Lack of neprilysin suffices to generate
murine amyloid-like deposits in the brain and behavioral deficit in
vivo". Journal of Neuroscience Research
84 (8): 1871–8. doi:10.1002/jnr.21074.
PMID 16998901.
- ^ Iwata, Nobuhisa; Satoshi Tsubuki, Yoshie
Takaki, Kaori Watanabe, Misaki Sekiguchi, Emi Hosoki, Maho
Kawashima-Morishima, Hahn-Jun Lee, Emi Hama, Yoko Sekine-Aizawa and
Takaomi C. Saido (February 2000). "Identification of the major
Abeta1-42-degrading catabolic pathway in brain parenchyma:
suppression leads to biochemical and pathological deposition".
Nature Medicine 6 (2): 143–50. doi:10.1038/72237. PMID 10655101.
- ^ Iwata, Nobuhisa; Makoto Higuchi and
Takaomi C. Saido (November 2005). "Metabolism of amyloid-beta
peptide and Alzheimer's disease". Pharmacology &
Therapeutics 108 (2): 129–48. doi:10.1016/j.pharmthera.2005.03.010. PMID 16112736.
- ^ Hama, Emi; Takaomi C. Saido (2005).
"Etiology of sporadic Alzheimer's disease: somatostatin,
neprilysin, and amyloid beta peptide". Medical Hypotheses
65 (3): 498–500. doi:10.1016/j.mehy.2005.02.045. PMID 15921860.
- ^ Wang, Deng-Shun; Nobuhisa Iwata, Emi Hama,
Takaomi C. Saido and Dennis W. Dickson (October 2003). "Oxidized
neprilysin in aging and Alzheimer's disease brains".
Biochemical and Biophysical Research Communications
310 (1): 236–41. doi:10.1016/j.bbrc.2003.09.003. PMID 14511676.
- ^ Sahli, Stefan; Bernhard Stump, Tobias
Welti, W. Bernd Schweizer, François Diederich, Denise Blum-Kaelin,
Johannes D. Aebi and Hans-Joachim Böhm (April 2005). "A New Class
of Inhibitors for the Metalloprotease Neprilysin Based on a Central
Imidazole Scaffold". Helvetica Chimica Acta
88 (4): 707–730. doi:10.1002/hlca.200590050.
- ^ Oefner, C.; B. P. Roques, M.-C.
Fournie-Zaluski and G. E. Dale (February 2004). "Structural
analysis of neprilysin with various specific and potent
inhibitors". Acta
Crystallographica Section D Biological Crystallography
60, prt 2: 392–396. doi:10.1107/S0907444903027410. PMID 14747736.
- ^ Velasquez, Elsa F.; Molly Yancovitz, Anna
Pavlick, Russell Berman, Richard Shapiro, Dusan Bogunovic, David
O'Neill, Yi-Lo Yu, Joanna Spira, Paul J Christos, Xi Kathy Zhou,
Madhu Mazumdar4, David M Nanus, Leonard Liebes, Nina Bhardwaj,
David Polsky and Iman Osman (January 2007). "Clinical relevance of
Neutral Endopeptidase (NEP/CD10) in melanoma". Journal of
Translational Medicine 5 (2): 2. doi:10.1186/1479-5876-5-2. PMID 17207277.
- ^ Cohen, Andrea J.; Paul A. Bunn, Wilbur
Franklin, Catherine Magill-Solc, Christa Hartmann, Barbara
Heifrich, Laura Gilman, Joy Folkvord, Karen Helm, and York E.
Miller (15 February 1996). "Neutral endopeptidase:
variable expression in human lung, inactivation in lung cancer, and
modulation of peptide-induced calcium flux". Cancer Research 56
(4): 831–9. PMID 8631021. http://cancerres.aacrjournals.org/cgi/reprint/56/4/831. Retrieved
2006-03-11.
External
links
|
Proteins: clusters of differentiation
(see also list of human
clusters of differentiation) |
|
|
1-50 |
CD1
( a-c, 1A, 1D, 1E) · CD2 ·
CD3 ( γ, δ, ε) · CD4 ·
CD5 · CD6 ·
CD7 · CD8 ( a) · CD9 ·
CD10 · CD11 ( a, b, c) ·
CD13 · CD14 ·
CD15 · CD16 ( A, B) · CD18 ·
CD19 · CD20 ·
CD21 · CD22 ·
CD23 · CD24 ·
CD25 · CD26 · CD27 ·
CD28 · CD29 ·
CD30 · CD31 ·
CD32 ( A, B) · CD33 ·
CD34 · CD35 · CD36 ·
CD37 · CD38 ·
CD39 · CD40 · CD41 · CD42 ( a, b, c, d) · CD43 ·
CD44 · CD45 · CD46 ·
CD47 · CD48 ·
CD49 ( a, b, c, d, e, f) ·
CD50
|
|
|
51-100 |
CD51 · CD52 ·
CD53 · CD54 · CD55 · CD56 · CD57 · CD58 ·
CD59 · CD61 ·
CD62 ( E, L, P) · CD63 ·
CD64 ( A, B, C) · CD66 ( a, b, c, d, e, f) · CD68 ·
CD69 · CD70 ·
CD71 · CD72 ·
CD73 · CD74 ·
CD78 · CD79 ( a, b) · CD80 ·
CD81 · CD82 · CD83 ·
CD84 · CD85 ( a, d, e, h, j, k) · CD86 ·
CD87 · CD88 · CD89 ·
CD90 · CD91- CD92 · CD93 ·
CD94 · CD95 · CD97 ·
CD98 · CD99 ·
CD100
|
|
|
101-150 |
|
|
|
151-200 |
CD151 · CD152 · CD153 · CD154 · CD155 · CD156 ( a, b, c) · CD157 · CD158 ( a, d, e, i, k) · CD159 ( a, c) ·
CD160 · CD161 · CD162 · CD163 · CD164 · CD166 · CD167 ( a, b) · CD168 · CD169 · CD170 · CD171 · CD172 ( a, b, g) · CD174 · CD177 · CD178 · CD179 ( a, b) ·
CD181 · CD182 · CD183 · CD184 · CD185 · CD186 · CD191 · CD192 · CD193 · CD194 · CD195 · CD196 · CD197 · CDw198 · CDw199 · CD200
|
|
|
201-250 |
|
|
|
251-300 |
|
|
|
301-350 |
|
|
| Tumor markers |
|
| Blood |
|
|
|
Endocrine |
|
|
| Nervous
system |
|
|
Cardiovascular/
respiratory |
|
|
|
Digestive |
|
|
Reproductive/
urinary/
breast |
|
|
| General
histology |
|
|
|
Musculoskeletal |
|
|
| Note: all
are peptide except normetanephrine and PCA3. |
|
|
PDB Gallery |
|
|
|
|
1dmt: STRUCTURE OF HUMAN NEUTRAL ENDOPEPTIDASE
COMPLEXED WITH PHOSPHORAMIDON
|
|
|
|
1r1h: STRUCTURAL ANALYSIS OF NEPRILYSIN WITH
VARIOUS SPECIFIC AND POTENT INHIBITORS
|
|
|
|
1r1i: STRUCTURAL ANALYSIS OF NEPRILYSIN WITH
VARIOUS SPECIFIC AND POTENT INHIBITORS
|
|
|
|
1r1j: STRUCTURAL ANALYSIS OF NEPRILYSIN WITH
VARIOUS SPECIFIC AND POTENT INHIBITORS
|
|
|
|
1y8j: Crystal Structure of human NEP complexed
with an imidazo[4,5-c]pyridine inhibitor
|
|
|
|